Abstract
Abstract
Xanthomas are frequently a sign of hypercholesterolaemia or other dyslipidaemias. Investigating and treating the underlying lipid disorders reduces the risk of their systemic complications: principally atherosclerotic cardiovascular disease and acute pancreatitis. This chapter describes the different xanthomas, the molecular basis of the associated dyslipidaemias and the expanding array of hypolipidaemic drugs.